← Back to Search

DxFLEX 10C Clinical Study

N/A
Waitlist Available
Research Sponsored by Beckman Coulter, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Timeline
Screening 3 weeks
Treatment Varies
Follow Up immediately after the analysis
Awards & highlights
No Placebo-Only Group

Summary

A multi-center method comparison study is designed per CLSI-EP09 A3. This study compares the qualitative immunophenotype agreement between DxFLEX and Navios EX to demonstrate the accuracy of the DxFLEX-10C system. A series of precision studies will be conducted with each focusing on different aspects of the DxFLEX-10C system.

Eligible Conditions
  • Blood Cancers

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~immediately after the analysis
This trial's timeline: 3 weeks for screening, Varies for treatment, and immediately after the analysis for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Flow immunophenotyped normal and abnormal

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Group I: Hematologically normalExperimental Treatment1 Intervention
Based on immunophenotyping
Group II: Hematologically abnormalExperimental Treatment1 Intervention
Based on immunophenotyping
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
DxFLEX 10C
2022
N/A
~530

Find a Location

Who is running the clinical trial?

Beckman Coulter, Inc.Lead Sponsor
37 Previous Clinical Trials
443,258 Total Patients Enrolled
Guoyan Cheng, PhDStudy DirectorBeckman Coulter, Inc.
~144 spots leftby Dec 2025